Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison
Completed
- Conditions
- Non-metastatic Hepatocellular Carcinoma
- Registration Number
- NCT04823715
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Patients with non-metastatic unresectable hepatocellular carcinoma
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 163
Inclusion Criteria
- Age ≥18 years of age
- ECOG 0-2
- Histologically proven hepatocellular carcinoma or proven according to radiological and biochemical criteria (EASL-AASLD) in cirrhotic patients
- Child-Pugh class A
- Absence of truncular or lobar portal vein invasion, or suprahepatic vein invasion
Exclusion Criteria
- Uncontrolled replication of hepatitis B virus
- Transplanted liver
- Previous abdominal irradiation
- Previous treatment of HCC with systemic therapy, or with surgical resection in the 2 previous years
- Metastatic illness
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease-free survival of the patient after start of treatment Within 10 years after the treatment (surgical resection or TACE) Disease-Free Survival (DFS) defined as the time (in months) between the treatment (surgical resection or TACE) and the diagnostic of local, locoregional or distant recurrence, or date of death from any cause; patients who are alive or lost to follow-up at the time of the analysis will be censored on the last follow-up date; patients who have received a liver transplant for non-carcinologic reason will be censored on the date of transplantation.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Croix-Rousse Hospital, Hospices Civils de Lyon
🇫🇷Lyon, France
Croix-Rousse Hospital, Hospices Civils de Lyon🇫🇷Lyon, France